The latest price target for BioLine Rx (NASDAQ:BLRX) was reported by HC Wainwright & Co. on November 25, 2024. The analyst firm set a price target for $9.00 expecting BLRX to rise to within 12 months (a possible 3775.97% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for BioLine Rx (NASDAQ:BLRX) was provided by HC Wainwright & Co., and BioLine Rx maintained their buy rating.

There is no last upgrade for BioLine Rx

There is no last downgrade for BioLine Rx.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLine Rx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLine Rx was filed on November 25, 2024 so you should expect the next rating to be made available sometime around November 25, 2025.

While ratings are subjective and will change, the latest BioLine Rx (BLRX) rating was a maintained with a price target of $21.00 to $9.00. The current price BioLine Rx (BLRX) is trading at is $0.23, which is out of the analyst’s predicted range.